Two observations raising questions about risk factors of cutaneous necrosis induced by terlipressin (Glypressin®)

Dermatology

Volumn 218, Issue 4, 2009, Pages 334-337

  Mégarbané, Hala ^a,c   Barete, Stéphane ^a   Khosrotehrani, Kiarash ^a   Izzedine, Hassan ^b   Moguelet, Philippe ^a   Chosidow, Olivier ^a   Frances, Camille ^a   Aractingi, Selim ^a  

^a HÔPITAL TENON   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF BALAMAND   (Lebanon)

Author keywords

Cancer; Drug side effects; Skin necrosis; Terlipressin

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; DOPAMINE; NORADRENALIN; TERLIPRESSIN;

AGED; ARTICLE; CASE REPORT; CYANOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; HEPATORENAL SYNDROME; HISTOPATHOLOGY; HUMAN; HYPOVOLEMIA; LIVEDO RETICULARIS; MALE; METASTASIS; PRESSOR RESPONSE; PRIORITY JOURNAL; PURPURA; RISK FACTOR; SEPTIC SHOCK; SKIN BIOPSY; SKIN CAPILLARY; SKIN NECROSIS;

AGED; HUMANS; ISCHEMIA; LYPRESSIN; MALE; NECROSIS; RISK FACTORS; SKIN; SKIN DISEASES; VASOCONSTRICTOR AGENTS;

EID: 67651089610     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000195676     Document Type: Article

References (16)

1. Kam PCA, Williams S, Yoong FFY: Vasopressin and terlipressin: pharmacology and its clinical relevance. Anesthesia 2004; 59: 993-1001. (Pubitemid 39307237)
2. Ortega R, Gines P, Uriz J, et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948.
3. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK: Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-156. (Pubitemid 36349860)
4. Delmas A, Leone M, Rousseau S, Albanese J, Martin C: Clinical review: vasopressin and terlipressin in septic shock patients. Crit Care 2005; 9: 212-222. (Pubitemid 40425448)
5. Moreau R, Lebrec D: The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006; 43: 385-394.
6. Halimi C, Bonnard P, Bernard B, et al: Effect of terlipressin (Glypressin® ) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-158. (Pubitemid 34163994)
7. Colle I, Durand F, Pessione F, et al: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-888.
8. Moreau R, Durand F, Poynard T, et al: Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-930. (Pubitemid 34267275)
9. Willems MG, Schoenemann J, Rey C, Schäfer H, Lindecken KD: Ischemia of the cecum caused by glycylpressin. Leber Magen Darm 1985; 15: 165-168.
10. Borrego R, Lopez-Herce J, Mencia S, Carillo A, Sancho L, Bustinza A: Severe ischemia of the lower limb and of the intestine associated with systemic vasoconstictor therapy and femoral arterial catheterization. Pediatr Crit Care Med 2006; 7: 267-269. (Pubitemid 43778599)
11. Vaccaro F, Giorgi A, Riggio O, De Santis A, Laviano A, Rossi-Fanelli F: Is spontaneous peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis 2003; 35: 503-506. (Pubitemid 41070445)
12. Rosario R, Lalanne B, Lebre P, et al: Myocardial infarction after injection of terlipressin for digestive hemorrhage. Gastroenterol Clin Biol 1996; 20: 712-713. (Pubitemid 26323071)
13. Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R: The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004; 24: 1050-1063. (Pubitemid 39025204)
14. Hadengue A, Gadano A, Moreau R, et al: Beneficial effects of the 2-day administration of terlipresssin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-570. (Pubitemid 28484945)
15. Lipsker D, Kara F: Retiform purpura. N Engl J Med 2008; 358: 2.
16. Dunser MW, Mayr AJ, Tur A, et al: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003; 31: 1394-1398. (Pubitemid 36583849)